Views & Analysis Steps to building a more patient-centric industry Lack of access, strict regulations, and demanding schedules have made it extremely difficult for patients to participate in clinical trials.
News Otsuka eyes early filing of IgAN drug after phase 3 readout Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.